title: [Anti-tumor immune responses of nanoemulsion-encapsulated MHS vaccine].
abstract: OBJECTIVE
  To prepare nanoemulsion-encapsulated MAGE1-Hsp70/SEA and to evaluate its anti-tumor effects in mouse.
  
  
  METHODS
  Nanoemulsion vaccine NE(MHS) was prepared using magnetic ultrasound methods and used to immunize C57BL/6 mice. The cellular immune responses were detected by IFN-gamma ELISPOT and LDH release assay. The tumor challenge assay was performed too.
  
  
  RESULTS
  (1) The mean size of NE(MHS) was (20+/-5) nm. The encapsulation rate was 87% and the nanoemulsion vaccine had a good stability. (2) The frequency of MAGE-1 specific CTL and cytotoxicity of CTL to B16-MAGE-1 cells were both greatly enhanced in immunization group than those in control group (P<0.05). NE(MHS) could significantly delay the appearance of tumors and increase the percentage of tumor-free mice.
  
  
  CONCLUSIONS
  The nanoemulsion had excellent physical and chemical characteristics. It could elicit MAGE-1-specific cellular immune response and anti-tumor effects against the MAGE-1-expressing tumor.
authors.affiliation: Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. geweidr@fmmu.edu.cn
authors.forename: Wei
authors.initials: W
authors.lastname: Ge
authors.forename: Yu-jing
authors.initials: YJ
authors.lastname: Sun
authors.forename: Yuan
authors.initials: Y
authors.lastname: Li
authors.forename: Shan-hong
authors.initials: SH
authors.lastname: Zhang
authors.forename: Xiu-min
authors.initials: XM
authors.lastname: Zhang
authors.forename: Yang
authors.initials: Y
authors.lastname: Huang
authors.forename: Pei-zhen
authors.initials: PZ
authors.lastname: Hu
authors.forename: Yan-fang
authors.initials: YF
authors.lastname: Sui
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage* / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage*; D007114:Immunization; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000276:immunology; D058950:Melanoma-Specific Antigens; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000008:administration & dosage / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018840:HSP70 Heat-Shock Proteins; C072011:MAGEA1 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D011993:Recombinant Fusion Proteins; D007371:Interferon-gamma